Cyteir Therapeutics, Inc. CYTT
3.01
0.00
0.00%
as of 31 May
- Market cap
- $108.7M
- P/E
- 0.0×
Follow CYTT
Growth Flags
show if company had growth for consecutive years
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 9.72 | 1.13 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 23.10 | 11.62 |
High Price
|
|||
| — | — | — | — | — | — | — | 31 | 40 | 46 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 0 | — | — | — |
Revenue
|
|||
| — | — | — | — | — | — | (2,587.50%) | 0.00% | 0.00% | 0.00% |
Gross Margin
|
|||
| — | — | — | — | — | — | (15) | (21) | (42) | (46) |
EBT
|
|||
| — | — | — | — | — | — | (188,050.00%) | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | 0 | — | (15) | (21) | (42) | (46) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 1 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (3.42) | (13.60) | (2.16) | (1.31) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (3.99) | (12.11) | (1.85) | (1.21) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | (0.56) | (0.06) | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | — | — | (3.99) | (12.66) | (1.91) | (1.21) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | 6.61 | (31.37) | 9.61 | 4.15 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 4 | 2 | 19 | 35 |
Shares
|
|||
| — | — | — | — | — | — | 0.00 | — | — | — |
PE Ratio
|
|||
| — | — | — | — | — | — | 0.00 | — | — | — |
PS Ratio
|
|||
| — | — | — | — | — | — | 0.20 | — | — | — |
PB Ratio
|
|||
| — | — | — | — | — | — | 0.00 | — | — | — |
EV/Sales
|
|||
| — | — | — | — | — | — | 5.87 | — | — | — |
EV/FCF
|
|||
| — | — | — | — | — | — | (18) | (19) | (36) | (43) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | (1) | (1) | 0 |
Capex
|
|||
| — | — | — | — | — | — | (18) | (19) | (37) | (43) |
FCF
|
|||
| — | — | — | — | — | — | 28 | 9 | 186 | 144 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | 2 |
Total Debt
|
|||
| — | — | — | — | — | — | (29) | (11) | (190) | (147) |
Net Debt
|
|||
| — | — | — | — | — | — | 29 | (48) | 187 | 146 |
Sh' Equity
|
|||
| — | — | — | — | — | — | (95.92%) | (92.33%) | (40.29%) | (26.42%) |
ROA
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | 39.40% | 54.53% | (60.50%) | (27.62%) |
ROE
|
|||
predictions in italic, sparklines do not include predictions
Fiscal years to Dec 2019
Cyteir Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BDTX Black Diamond Therapeutics, Inc. | $108.6M | 0.0× | Compare |
| PYPD PolyPid Ltd. | $108.9M | 0.0× | Compare |
| EQ Equillium, Inc. | $109.1M | 0.0× | Compare |
| BMEA Biomea Fusion, Inc. | $108.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GNLX Genelux Corporation | $110.0M | 0.0× | Compare |
| RANI Rani Therapeutics Holdings, Inc. | $107.3M | 0.0× | Compare |
| VANI Vivani Medical, Inc. | $111.0M | 0.0× | Compare |
| KZIA Novogen Limited | $111.8M | 0.0× | Compare |
Cyteir Therapeutics, Inc. (CYTT) key facts
- Cyteir Therapeutics, Inc. (CYTT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of May 31, 2024, CYTT traded at $3.01, a market capitalization of $108.7 million.
- Return on equity was −27.6% and debt-to-equity 0.00.
Cyteir Therapeutics, Inc. (CYTT) Latest News
No news matches these filters.